SCOPUS 정보 검색 플랫폼

Journal of Thoracic and Cardiovascular Surgery

Volumn 142, Issue 2, 2011, Pages 472-

A critical appraisal of pexelizumab treatment in patients undergoing coronary artery bypass grafting

(3) Lin, Gen Min a Li, Yi Hwei b Han, Chih Lu c

a HUALIEN ARMED FORCES GENERAL HOSPITAL (Taiwan)

b TZU CHI UNIVERSITY (Taiwan)

c TAIPEI VETERANS GENERAL HOSPITAL (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PEXELIZUMAB;

CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; HEART INFARCTION; HEART PROTECTION; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; REPERFUSION INJURY; SURGICAL PATIENT; THROMBOCYTE AGGREGATION;

ANTIBODIES, MONOCLONAL; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; SINGLE-CHAIN ANTIBODIES;

EID: 79960395020 PISSN: 00225223 EISSN: 1097685X Source Type: Journal
DOI: 10.1016/j.jtcvs.2011.03.030 Document Type: Letter

Times cited : (1)

References (5)

1
- 79960428928
- Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG i and II trials
- Epub Sep 27
- Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg. Epub 2010 Sep 27.
- (2010) J Thorac Cardiovasc Surg
- Smith, P.K.¹ Shernan, S.K.² Chen, J.C.³ Carrier, M.⁴ Verrier, E.D.⁵ Adams, P.X.⁶

2
- 2442613898
- Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial
- DOI 10.1001/jama.291.19.2319
- E.D. Verrier, S.K. Shernan, K.M. Taylor, F. Van de Werf, M.F. Newman, and J.C. Chen Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial JAMA 291 2004 2319 2327 (Pubitemid 38656298)
- (2004) Journal of the American Medical Association , vol.291 , Issue.19 , pp. 2319-2327
- Verrier, E.D.¹ Shernan, S.K.² Taylor, K.M.³ Van De Werf, F.⁴ Newman, M.F.⁵ Chen, J.C.⁶ Carrier, M.⁷ Haverich, A.⁸ Malloy, K.J.⁹ Adams, P.X.¹⁰ Todaro, T.G.¹¹ Mojcik, C.F.¹² Rollins, S.A.¹³ Levy, J.H.¹⁴

3
- 0029029540
- The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation
- M. Røger, K. Høgsen, P.A. Holme, T.S. Halstensen, T.E. Mollnes, and T. Hovig The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation Platelet 6 1995 160 168
- (1995) Platelet , vol.6 , pp. 160-168
- Røger, M.¹ Høgsen, K.² Holme, P.A.³ Halstensen, T.S.⁴ Mollnes, T.E.⁵ Hovig, T.⁶

4
- 78651422977
- Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors
- G.M. Lin, K.M. Chu, and C.L. Han Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitors Int J Cardiol 146 2010 280 282
- (2010) Int J Cardiol , vol.146 , pp. 280-282
- Lin, G.M.¹ Chu, K.M.² Han, C.L.³

5
- 79951953841
- Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization
- G.M. Lin, Y.H. Li, S.H. Wen, S.Y. Chen, K.M. Chu, and C.L. Han Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization Int J Cardiol 147 2011 340 341
- (2011) Int J Cardiol , vol.147 , pp. 340-341
- Lin, G.M.¹ Li, Y.H.² Wen, S.H.³ Chen, S.Y.⁴ Chu, K.M.⁵ Han, C.L.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.